Login to Your Account



After Pfizer, Novo Nordisk Walks

Second Inhaled Insulin Down; Firms, Analysts Keeping Faith

By Randall Osborne


Monday, January 21, 2008
The decision last week by Novo Nordisk AS to drop its Phase III inhaled-insulin program mildly stung licensor Aradigm Corp., putting observers in mind of Pfizer Inc.'s dump of Exubera in October - a surprise maneuver that dented shares of partner Nektar Therapeutics Inc. - and leaving investors with chips on other, similar efforts waiting to exhale. Stay in or get out? (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription